03039nas a2200229 4500000000100000008004100001260002600042100001400068700001400082700001300096700001500109700001600124700001800140700001600158700001200174700001200186700001400198245007300212856013900285300000700424520237800431 2021 d bPolicy Cures Research 1 aChapman N 1 aDoubell A 1 aTuttle A 1 aBarnsley P 1 aGoldstein M 1 aOversteegen L 1 aChowdhary V 1 aBorri J 1 aHynen A 1 aKearney M 00 aG-FINDER - Neglected disease research and development: Where to now? uhttps://policy-cures-website-assets.s3.ap-southeast-2.amazonaws.com/wp-content/uploads/2021/04/15055816/G-FINDER-2020_Final-Report.pdf a39 3 aEach year since 2007, G-FINDER has provided policy-makers, donors, researchers and industry with a comprehensive analysis of global investment into research and development of new products to prevent, diagnose, control or cure neglected diseases in developing countries, making it the gold standard in tracking and reporting global funding for neglected disease R&D.
This year’s report, the thirteenth overall, focuses on investments made in participants’ 2019 financial year (‘FY2019’). Data was collected during 2020, with a longer than normal survey period to allow for maximum survey participation despite the COVID-19 pandemic. As a result, this report is being published later than usual, and thus at an even greater than normal remove from the funding year
being analysed. For this reason we’ve opted for a slightly different report format than in previous years, offering readers a more consolidated narrative and streamlined analysis, particularly of the disease-specific R&D funding trends.
The full suite of graphs and tables provided in previous reports can now be created on demand using our online data portal: https://gfinderdata.policycuresresearch.org/
This year’s report contains an overview of neglected disease funding, measured in 2019 US dollars, including:
• figures for individual diseases and product categories;
• analysis of public, philanthropic and (anonymised, aggregated) private neglected disease funders;
• details of the flow of funds to product development partnerships, other intermediaries and directly to researchers and developers; and
• a discussion of this year’s key findings and how they fit with longer term trends, including the future impact of COVID-19 on funding for neglected diseases.
The global pandemic did reduce participation in the survey, though not as much we had feared.
Thanks to the commitment of survey respondents, data from funders representing nearly 96% of our FY2018 funding total was captured in our survey of FY2019 R&D funding. While the overall effect of COVID-19 on participation was relatively slight, some areas were
disproportionately impacted by the absence of data for FY2019. All instances in which headline funding totals are potentially misleading due to survey participation effects are highlighted throughout the report.